Sanofi Gets Marketing Nod From CDSCO To Sell Its Diabetes Drug
Sanofi India on Monday informed that it has received marketing authorization for its diabetes drug Soliqua (in a pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO).
Soliqua is indicated as a treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once-daily dosing of pre-filled pens in fixed-ratio combination (10-40 and 30-60) of insulin glargine and lixisenatide.
“With approximately 74 million Indians (between the ages of 20-79 years) living with diabetes, healthcare professionals need more treatment options to customize diabetes care for them. Soliqua is the latest addition to our comprehensive diabetes portfolio (OADs and insulins) indicated for obese people who are living with insufficiently controlled diabetes. It will allow physicians to provide more tailored solutions for better diabetes management,” stated Cyrus AibaraHead – Diabetes Business Unit, Sanofi (India).
The company said that Soliqua (10-40 and 30-60 prefilled pens) is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.
